Cellular Biomedicine Group is a China-based company that focuses on developing proprietary cell therapies for cancer and degenerative diseases. Founded in 2009, the company conducts immuno-oncology and stem cell clinical trials in China and operates integrated GMP facilities. These facilities consist of twelve independent cell production lines and adhere to both China and U.S. GMP standards. The company's last Series A investment, totaling $120.00M, was secured on 28 September 2021. Notable investors in this round include GIC, TF Capital, YF Capital, Sequoia Capital China, and AstraZeneca. With a focus on biotechnology, health and wellness, and medical devices, Cellular Biomedicine Group is positioned to make a significant impact in the field of cell therapy and regenerative medicine.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $120.00M | 5 |
|
28 Sep 2021 |
| Post-IPO Equity | $30.60M | 1 |
|
07 Feb 2018 |
| Post-IPO Equity | $43.13M | 1 | Wuhan Dangdai Science & Technology Industries Group | 05 Feb 2016 |
| Post-IPO Equity | $6.91M | - | 11 Apr 2014 | |
| Post-IPO Equity | $3.01M | - | 26 Jul 2013 |
No recent news or press coverage available for Celllular Biomedicine Group.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
